Home » Business News » 2014 » November » November 6, 2014

Bavarian Nordic to Host Third Quarter 2014 Results Conference Call

November 6, 2014 - London

KVISTGAARD, Denmark - November 6, 2014 - Bavarian Nordic A/S (OMX:BAVA, OTC: BVNRY) will announce its 2014 third quarter results on Thursday, November 13, 2014.

The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present the interim results followed by a Q&A session.

Dial-in numbers for the conference call are:
Denmark: +45 32 72 80 18
UK: +44 (0) 844 571 8957
USA: +1 866 682 8490

A live and archived webcast of the call and relevant slides will be available at

U.S.: Seth Lewis, Vice President, Investor Relations. Phone: + 1 978-298-5654
Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and manufacturing novel cancer immunotherapies and vaccines for infectious diseases. Lead product candidates are PROSTVAC®, an immunotherapy product candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 clinical trial and IMVAMUNE®, a non-replicating smallpox vaccine candidate in Phase 3 development, which is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. IMVAMUNE is approved in Canada and in the European Union, where it is marketed under the trade name IMVANEX®. Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol BVNRY. For more information, visit

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire



Comment on this story